NCT05992142 - ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions

Ulcerative Colitis

Interventions

DRUG

5-ASA

Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit

Trial Locations (16)

Unknown

Imelda Ziekenhuis, Bonheiden

Hôpital Erasme, Brussels

Universitair Ziekenhuis Antwerpen, Edegem

Ziekenhuis Oost-Limburg, Genk

AZ Sint-Lucas Gent, Ghent

Universitair Ziekenhuis Gent, Ghent

AZ Groeninge, Kortrijk

CHU de Liège - Site Sart Tilman, Liège

Groupe santé CHC Clinique du MontLégia, Liège

AZ Voorkempen Malle, Malle

AZ Damiaan, Ostend

AZ Delta, Roeselare

Sint-Andries ziekenhuis Tielt, Tielt

AZ Vesalius, Tongeren

AZ Turnhout, Turnhout

CHU UCL Namur -Site Mont Godinne, Yvoir